Joseph Pantginis

The share price of Tetralogic Pharmaceuticals Corp (NASDAQ: TLOG) has declined 70.54 percent year to date, touching a low of $1.37 on December 16. Roth Capital’s Joseph Pantginis has initiated coverage of the company with a Buy rating and price target of $5. Pantginis believes that...

Prima BioMed Ltd (ADR) (NASDAQ: PBMD) shares jumped 13 percent in premarket trading on December 31. Roth Capital’s Joseph Pantginis initiated coverage of the company with a Buy rating and a price target of $6. Initial clinical efficacy of LAG-3 has been promising, putting the...

Shares of Aduro BioTech Inc (NASDAQ: ADRO) have appreciated 46.14 percent over the past three months, to reach $33.63 on December 16. Roth Capital’s Joseph Pantginis has reiterated a Buy rating on the company, with a price target of $68. While adding the stock to the ROTH Focus List...

In a report published Monday, Roth Capital analyst Joseph Pantginis downgraded the rating on Keryx Biopharmaceuticals (NASDAQ: KERX) from Buy to Neutral, while reducing the price target from $11 to $6 in view of the strong Auryxia headwinds. Keryx reported its 2Q15 EPS and revenue at ($0.26)...

Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) were trading higher by more than 3 percent Tuesday after the company announced a new global collaboration with Sanofi (NYSE: SNY) to "discover, develop and commercialize new antibody cancer treatments in the emerging field of immune-...

As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to “focus on names with definitive catalysts.” Though the analyst rates 15 biotech stocks, five are highlighted below. Celldex Therapeutics, Inc. (...

Shares of Cytokinetics, Inc. (NASDAQ: CYTK) surged 16 percent Wednesday following Roth Capital raising its price target on the company from $13 to $18. The analyst note cited four facets for its strengthened investment case: 1) "CYTK has shown its prowess in attracting significant...

Sunesis Pharmaceuticals, Inc.'s (NASDAQ: SNSS) failed cancer drug vosaroxin offers no reason for investors to give up hope on other companies' potential cures, an analyst said Tuesday. Sunesis said Tuesday its vosaroxin drug for acute myeloid leukemia failed to show effectiveness in a...